PK / PD of an antibody in the skin

Study Title: "An exploratory study to investigate the distribution of secukinumab (AIN457) in the interstitial fluid of the skin using open flow microperfusion after a single subcutaneous injection of 300 mg in healthy volunteers and psoriatic patients"

Challenge

The sponsor, Novartis Pharma AG, has developed the antibody "secukinumab". Secukinumab is a monoclonal antibody (a protein that specifically binds to another molecule), which selectively stops the effect of an endogenous protein called interleukin-17A (IL- 17A). IL-17A plays a role in many different types of inflammatory diseases such as psoriasis. Clinical studies with patients have already proved its effect. This study aimed to determine the concentration of the antibody and its effect on local inflammatory markers directly at the site of action in the skin (dermis) by using dermal open flow microperfusion (dOFM).

Solution

The concentration of the antibody in the skin and in the serum of healthy volunteers and psoriatic patients on day 8 and day 15 was determined following a single-dose subcutaneous injection of the antibody. The concentrations of selected inflammatory markers (cytokines) in the skin and in serum were examined on days 1, 8 and 15.

Results

Antibodies and inflammatory markers were successfully detected in the skin by dOFM. The study showed that on day 8 and 15 after the injection, a sufficiently high and stable concentration of the antibody is achieved at the proposed site of action (skin). The measurement of inflammatory markers revealed reduced levels in lesional skin. The effect of the antibody at the planned site of action was detected by using open flow microperfusion.

 

The details of the study were presented at several international conferences (e.g. AAPS National Biotechnology Conference 2014, Society for Investigative Dermatology 2014).

What our clients say

 

"Lorit  des peresen ectibus elit liquam apietur iatibus dolut erias volupta di debam apietur iatibus dolut erias voluitat eseque qui delique qu seri con es o elm, volores tiorum, psanis sund? Cium des peresen ectibus e luptatque aut qui ipsam, volores tiorum, psanis su es as mint. Aui aturias ma que ea es aut qui ipsam, volores tiorum, psanis sund? Alm, volores tiorum, psanis sund? "

Name Experte, XY

Contact Us

Please reach out and we will answer
your questions,react to your ideas and
deal with your requirements straight away.

 

Keep in touch